CD Capital Natural Resources Fund III Monetization of Filo Mining stake for C$158.3 Million
12.1.2023 20:23:00 EET | Business Wire | Press release
CD Capital Natural Resources Fund III ("CD Capital”) successfully monetizes its equity investment in Filo Mining for a total consideration of C$158.3 million.
Filo Mining is a Canadian exploration and development company focused on advancing its 100% owned Filo del Sol copper-gold-silver deposit located in Chile's Region III and adjacent San Juan Province, Argentina. CD took a strategic stake in the company back in 2020 enabling an expansion program of drilling to define deeper sulphide mineralisation. The Filo del Sol project has since been described as a high-sulphidation epithermal copper-gold-silver deposit associated with one or more large porphyry copper-gold systems with overlapping mineralizing events.
This drilling, undertaken over the past couple of years, has delivered some of the most spectacular mineralised intercepts of copper and gold the market has witnessed in decades. Recent drill results, such as the recent announcement of drill hole FSDH071 intersected 1,028.0m at 1.16% CuEq from a depth of 292m, including;172.0m at 2.14% CuEq from 408.0m and 237.5m at 1.49% CuEq from 776.0m, continue this success.
CD Capital was one of the early institutional investors to finance the drilling at Filo and the exploration success has been witnessed not only by the markets but also with Filo Mining attracting investment from BHP, who precipitated a C$100m strategic investment into Filo Mining in May 2022.
CD Capital is proud to have been an early institutional investor, alongside the Lundin Group, to support and finance the exploration and project development. The drilling is proving to be transformative for the company and has positioned it for future growth, confirming CD Capital's vision in supporting the leadership of the Lundin Group and the Filo del Sol project.
Founder & CEO of CD Capital, Carmel Daniele, noted the eventual monetization of the fund’s holding in Filo Mining, was part of the fund's normal course of business and mandate terms, delivering a substantial multiple of invested capital since acquisition. The project has more to deliver and CD looks forward to seeing this project flourish into a leading global copper and gold producer. "CD Capital is proud to have been involved in one of the largest copper discoveries in decades and personally has been one of the highlights of my career to see it come into fruition. It has been a truly spectacular investment for CD Capital Fund III’s investors and we are confident Filo’s journey to more success will continue. We look forward to the opportunity of partnering up on similar world-class projects led by top tier management teams with a strong proven track record, such as the Lundin Group, through the combination of our long-term patient institutional capital and our sector expertise to unlock value from exciting future projects in the pipeline.”
Chairman of the board of Filo Mining, Adam Lundin, commented, "We are appreciative for the support from CD Capital, who again believed in the vision of a Lundin Group entity in its early days. The equity participation alongside the family at the beginning of COVID in 2020 allowed us to continue to advance Filo del Sol into what is turning into truly a world class discovery. I would also like to extend a special thanks to CD Capital’s Founder & CEO, Carmel Daniele, for her continued valuable contributions as a Board member of Filo Mining. It has been an amazing journey and we will continue to unlock more value from this fantastic asset. We look forward to creating further value for CD Capital investors on current and future ventures within the Lundin Group."
About CD Capital Group
Over the past 15 years, London based CD Capital has launched three Private Equity funds, having raised circa US$1 billion in long-term patient capital, predominantly from leading North American institutional investors, including endowments and foundations, family offices and corporate pension funds. CD Capital develops world-class projects globally in precious metals, critical metals for greening the world, as well as fertilisers for global food security. CD Capital has a unique focus on partnering up with repeat management teams that have a strong track record in successfully developing projects in Latin America, such as Brazil, Peru, Argentina, Guatemala as well as Canada, Finland, Greenland and Australia.
CD Capital was founded in 2006 by Ms Daniele, who was one of the first in London to set up a dedicated fund focused on private mining assets and winning the prestigious Mines & Money Fund Manager of the Year award in 2008. Since establishing CD Capital, Ms Daniele has built a world-class investment technical team of industry insiders and has been an active sponsor and employer of women studying mining geology at Imperial College, London, resulting in a successful nomination to the 100 Women in Mining for 2022.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230112005568/en/
Contact information
Dominic Chapman
Chief Financial Officer
ir@cd-capital.com
+44 (0) 207 389 1450
Carmel Daniele
Founder, CIO & CEO
ir@cd-capital.com
+44 (0) 207 389 1450
www.cd-capital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
